Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q2 Report 2019

August 7, 2019

Q1 Report 2019

May 9, 2019

Investor presentations

ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019

Click here for webcast

New York City

Friday, October 4 at 7:45 a.m. Eastern time (ET).

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

ObsEva Investor Presentation – April 2019

ObsEva Short Report 2018

Press Releases

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis

press release

November 20, 2015

Geneva, Switzerland, 20 November 2015 – ObsEva and Kissei Pharmaceutical Co., Ltd. (“Kissei”) today announced that they have entered into a…

Read more

ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2α Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor

press release

November 4, 2015

Geneva, Switzerland, 04 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…

Read more

ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer

press release

September 22, 2015

Geneva, Switzerland, 22 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…

Read more
1 35 36 37 38 39 40

General Meetings

ObsEva Annual General Meeting 2019

May 8, 2019

Read more

ObsEva Annual General Meeting 2018

May 9, 2018

Read more
1 2

Upcoming Events

Year End 2019 Financial Results week of 02 March 2020


March 2, 2020

Read more

Third Quarter 2019 Financial Results week of 11 November 2019


November 11, 2019

Read more

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy


October 17, 2019

Read more
1 2


ObsEva Switzerland Office

+41 (0)22 552 3840

ObsEva U.S. Office

+1 857 972 9364

Media Switzerland & Europe

Christophe Lamps
Dynamics Group
+41 79 476 26 87

Media United States

Marion Janic
RooneyPartners LLC
+1 212-223-4017

Investor relations

Clinical studies

HR Office

Charlotte Cadoux

CEO Office

+41 (0)22 552 1550


Sign up for news


* Type:

InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther

Read our privacy policy here.